Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/273208214?client_source=feed&format=rss
ghost rider spirit of vengeance hornets prince johan friso windows 8 logo anguilla gone with the wind michael jordan
Sailors, raise your hands.
You might have noticed, in Part 1, my contempt for the entitled laziness of some skippers. On reflection I must hedge. My portrait of a pampered ?yachtsman? might apply unfairly to the larger group of ?those who sail,? as was suggested by a recent visit to Portland Yacht Services.
At the end of November, I joined my neighbor Luke in examining a 25-foot sailboat at the PYS yard. Luke and his wife already own a sailboat, but he knows of my interest in sailing, and thought it would make a perfect ?first boat?. He knew the owner. And the price was right: free.
It taught me a little about the yachting world and a lot about myself. No facade of grim formality received us at the PYS office: just some friendly grey-haired guys with calculators. It was a refreshingly capitalist exchange. I was never so delighted to be an anonymous consumer.
Of course, the numbers they crunched did not sum to zero. First of all, there was a winter storage fee of more than $1,000. Shrink-wrap was a few hundred more. Spring launching, more. And the cutlass bearing is going to fail at some point?
So, even if Luke?s friend did give away his sailboat, I?d be knee deep in commitment before it ever touched the sea. It was a frightening thought, and it struck me that while I often pined for the comforts of a sailboat, they weren?t worth the headaches.
My acceptance of windsurfing as a cheap alternative to (traditional) sailing is, I realized, actually a preference. Though a year or two of sailing might cost no more than my $4,000 investment in windsurfing gear, I?d rather have the versatility of windsurfing than the comfort and range of a sailboat.
How much is it costing me to store my windsurfing equipment this winter? Zero dollars. Spring launching? Zero. Take it to the lake? Zero. There is something deeply gratifying about its human scale. I carry it to the water. Then it carries me. We can travel on either side of the water?s edge. It seems almost magical.
That is why, in planning my resumption of the trek, I opted for kayaking. While it lacks the alluring promise of a free ride, it fits perfectly with my freshly acquired ?amphibious? mandate: to travel by water ?with my bed on my back?, and, at any moment, take to shore and disappear.
?Roll or Die.?
So said the bumper of an old Volvo wagon that just pulled in to the East End landing with two kayaks on top. A short, athletic young woman bounded out of the driver?s seat. She wore a braid of jet-black hair, from which many wily strands had drifted. She walked, I thought, like a tomboy.
It was early September. The parking lot was full of kayaks, including mine. I was going out paddling to practice ?eskimo? rolls. Everyone else, it seemed, was part of a class. She was one of the instructors.
I told her I was heartened by the sentiment of ?Roll or Die?. For the Inuits who first developed the kayak (and the roll) in icy northern waters, it was literally true. In our warmer waters, and with modern gear, it?s easier to get back into a kayak. But any such ?recovery? is a poor substitute to rolling. In rough conditions, it could come down to ?Roll or Die?.
I had learned to roll last summer by watching YouTube videos. I didn?t even have a spray skirt yet. I flipped over, thrashed around a little bit, failed a few times, and then, to my great surprise, succeeded. Some days later I tried again, but failed completely. Not even close. The required movements seemed impossible to imagine from an upside-down point-of-view, with water all around and air underneath.
In late August of this summer, we visited my in-laws on Shelter Island, New York. I brought my kayak and a book on eskimo rolling and practiced in the pool for hours. I wanted a ?bomb-proof? roll, a dependable, instinctive roll. I studied techniques, variations and drawbacks, and gradually it became easier. I wore a diving mask so that I could see what I was doing, and to keep water out of my nose.
I was confident, I dare say ?prepared? for the second leg of my trip.
Source: http://mybraincancerdiary.com/2012/12/12/heron-part-5/
Azarenka NFL fantasy football Chris Kluwe Jennifer Granholm Tulane player injured frank ocean fox sports
MUMBAI (Reuters) - The rupee fell for a second session on Thursday, dragged by a late slide in the domestic stock market and a fall in the euro, with a crucial inflation number on Friday to give cues ahead of the central bank's rate setting meeting next week.
Shares fell for a fifth day as dealers booked profits in a market which has outperformed its regional peers in 2012 and seen capital inflows of over $20 billion.
The rupee has been supported in recent sessions by inflows on shares sales by state-run miner NMDC Ltd
About 30 percent of NMDC's $1.1 billion share sale was picked up by foreign investors, sources told Reuters.
Bharti's up to $830 million initial public offering was fully covered by Thursday, a day ahead of issue close.
The rupee's losses were also caused by a rebound in the global dollar on Thursday as investors looked past an expected Fed outcome and booked profits on short dollar positions.
"The recovery in the global dollar and a fall in stocks just turned the tide against the rupee," said Hemal Doshi, currency strategist at Geojit Comtrade.
"Unless the USD/INR closes below 54.25, it will stay in a 54.25-54.80 range."
The partially convertible rupee closed at 54.46/47 per dollar, weaker than its Wednesday's close of 54.32/33.
Investors are now looking forward to the inflation data on Friday, with a Reuters poll showing a 7.60 percent rise in October.
India's central bank is likely to hold rates steady on December 18, but views on a cash reserve ratio cut were split, a Reuters poll conducted before the data release showed.
Credit Agricole, however, expects the rupee to gain next year with a December-end target of 52 to the dollar.
"The INR is trading at relatively attractive levels in REER terms, and seems to have priced in many of the fundamental problems it faces," the brokerage said in a note, referring to the real effective exchange rate (REER).
In the offshore non-deliverable forwards, the one-month contract was at 54.78, while the three-month was at 55.31.
In the currency futures market, the most-traded near-month dollar/rupee contracts on the National Stock Exchange, the MCX-SX and the United Stock Exchange all closed at around 54.6450, with total traded volume of $5.2 billion.
(Editing by Anand Basu)
Source: http://news.yahoo.com/rupee-falls-2nd-day-local-shares-euro-drag-115250003--finance.html
college football scores khan academy Espn College Football Eddie Murphy died Suzanne Barr Clint Eastwood speech Maria Montessori
(Reuters) - A long-running legal dispute between Bank of America Corp
MBIA won the necessary consent of bondholders to change the terms of some of its debt last month, despite a move by Bank of America to thwart the change. That outcome has reduced the bank's negotiating leverage, increasing the likelihood of a settlement, the analysts wrote in a report dated Tuesday.
Bank of America, the second largest U.S. bank by assets, last week also said that it was proceeding with an offer to buy some of MBIA's bonds, which could be part of a settlement strategy, according to the report.
"We speculate that BofA is adding exposure to MBIA's capital structure to conceal the amount of a settlement so as to not set a precedent for negotiations with other litigants," analysts Rob Haines and Eric Axon wrote.
MBIA and Bank of America declined comment.
The legal wrangling is a major cloud hanging over both companies, which have struggled to recover from mortgage-related troubles from the financial crisis.
MBIA claims that Bank of America owes it billions of dollars over soured mortgages that it wants the bank to buy back. Bank of America says the insurer owes it billions over certain credit default swap transactions.
CreditSights said it expects a comprehensive settlement that would cover both issues.
MBIA proposed the changes to its debt on November 7 to eliminate the risk that it might be considered in default if a troubled insurance unit were put into rehabilitation or liquidation by the New York State Department of Financial Services.
MBIA said at the time that if there were such a default, it would have insufficient liquidity to make good on the notes and would probably immediately pursue other actions, including bankruptcy.
Bank of America countered with an offer to buy MBIA bonds, saying it believed the changes would increase the risk of MBIA's insurance unit being placed in rehabilitation or liquidation. That would jeopardize all policyholder claims, including Bank of America's, the bank said. But on November 26, MBIA said it won the necessary consent of bondholders to make the changes.
On December 5, Bank of America said it waived certain conditions in order to continue with its offer to buy MBIA bonds through Tuesday. It has not said whether it has extended the offer.
CreditSights said MBIA could avoid regulatory seizure for three to four years or potentially altogether if a settlement with Bank of America occurs.
Meanwhile, lawyers for MBIA were in New York State court on Wednesday arguing that at least $12.7 billion of the loans in question were defective. Bank of America's Countrywide mortgage unit disputed that fact.
The hearing is set to resume on Thursday.
Bank of America bought subprime lender Countrywide Financial in 2008.
(Reporting By Rick Rothacker in Charlotte, N.C. and Karen Freifeld in New York; Editing by Nick Zieminski and Leslie Gevirtz)
three stooges the three stooges the bee gees woodward keratosis pilaris rock and roll hall of fame 2012 brandon rios
In slightly puzzling news, Google appears to have pulled the Nexus 4 Android 4.2.x system images from its online repository of factory images. These files allow devices to be restored to their original state, so if something goes wrong when flashing a ROM or otherwise tinkering with your phone, there's an easy way back to stock.
Factory images for other Android 4.2 devices, such as the Nexus 10, Nexus 7, Nexus 7 3G and Galaxy Nexus remain on Google's site, so it'd appear whatever caused them to be withdrawn is specific to the Nexus 4.
Our best guess is that this might relate to the LTE situation on the Nexus 4. By changing a hidden setting, it's possible to use the N4 on LTE networks running on Band 4 (AWS), though this is not officially documented or approved by regulators. And that last part may be key -- if Google is preparing to patch this hidden LTE option out of the Nexus 4 -- as it'd be required to do to avoid falling foul of bodies like the FCC -- then clearing out earlier factory images might simply be a precaution. It's possible Google's looking to keep regulators happy by making it harder to find the earlier radio code that enabled this unlicensed LTE functionality. That's just speculation on our part, however, there may be a much more innocuous explanation.
In any case, we'll keep you posted on any further developments.
Source: Nexus Factory Images; via: theandroidsoul
Source: http://feedproxy.google.com/~r/androidcentral/~3/aDuMO_KX10A/story01.htm
bks new dark knight rises trailer khloe and lamar oklahoma city thunder rajon rondo sunoco titanic ii
By Alissa Figueroa
Rock Center
One day in 2005 Hamdi Ulukaya, owner of a small feta cheese company in upstate New York, took a tour that would change his life. As he walked through the 100-year-old yogurt factory, a handful of employees were busying themselves with the work of shutting the factory down.
?On the way back, I called my attorney and I said, ?I just saw a plant and I think I want to buy it,?? explains Ulukaya, a 40-year-old immigrant who grew up on a dairy farm in eastern Turkey. ?He said, "You?re really, really crazy. That's not going to happen.?"
But Ulukaya saw something in the defunct factory that no one else did: an opportunity to bring the yogurt of his youth to the masses. So using loans of less than $1 million, some backed by the Small Business Administration, he bought the plant.
Ulukaya spent the next two years developing the recipe for Chobani yogurt.
NBC News
Chobani founder Hamdi Ulukaya and Rock Center's Harry Smith.
?That place became my home,? Ulukaya told Rock Center's Harry Smith in an interview airing Thursday, Dec. 13 at 10pm/9CT on Rock Center with Brian Williams. ?It was lonely days, difficult days, a lot of question marks, a lot of pressure to see if I would make it to the next day.?
No longer does Ulukaya have to worry if his company will make its next payroll.
WATCH: Chobani founder on billion dollar Greek yogurt business
Since launching in 2007, Chobani has grown into a $1 billion business, according to Ulukaya, with no signs of slowing down. He also did something arguably more impressive: he changed what Americans eat.
Before Chobani came along, Greek yogurt sales in America were nearly nonexistent. Now, more than a third of the yogurt we eat is Greek, and Chobani is the biggest seller.
Ulukaya's personal wealth is now valued at $1.1 billion by the Bloomberg Billionaire's Index.
Impact on the local community
The good fortune, though, is not only his. Chobani's rise has been a lifeline for one of the most economically depressed parts of the country: rural upstate New York. This area was struggling long before the recession hit, with tens of thousands of manufacturing jobs disappearing in the last few decades.
?I expected the plant to sit there vacant [after Kraft left]. I had these visions of it becoming dilapidated and falling apart,? says Maria Wilcox, one of the four remaining Kraft workers that Ulukaya hired from New Berlin, the tiny town where the plant is located.?
Growing from those first few workers, Chobani now employs more than 1,300 people in upstate New York and has made $193 million in capital investments on the old factory.
?Other companies came and looked at the plant and the surrounding area and left. [Ulukaya] always had a vision for the plant here that included the community,? says New Berlin Mayor Terry Potter.? ?He?s brought a sense of rejuvenation to the community.?
Along with good-paying jobs, Chobani built New Berlin its first little league field, free of charge.
Chobani also trucks 4 million pounds of milk daily to its New Berlin factory from the area's 5,300 dairy farms. New York produced some 530 million pounds of yogurt in 2011 -- more than twice 2008 levels ? and a direct result of Greek yogurt production.
A new kind of CEO
Ulukaya has been able to accomplish all of this so quickly by bypassing many of the traditional models for business success, especially in the food industry. Instead of focus groups, consultants and big marketing campaigns, Ulukaya has focused on perfecting his product based on response from consumers. Ulukaya still has messages from customers (every single one) forwarded to his cell phone daily.
The company has been particularly good at harnessing the power of positive feedback online.
?The communication is so fast; you don't need huge money for the marketing or your voice to be heard,? says Ulukaya. ?It's a flat world.?
In fact, Chobani has only launched two television ad campaigns, the most recent during the 2012 London Olympics, for which they were an official sponsor. Ulukaya had to pull the ads because the factory couldn?t keep up with the increased demand.
Chobani runs on the idea that consumers? voices will shape the market; with the internet, word of mouth is a more valuable marketing tool than ads, says Ulukaya. This helps new guys on the scene make a big impact quickly. And, he adds, it?s their responsibility to challenge the status quo.
?It's a shame what's in the supermarkets today,? says Ulukaya. ?It doesn't have to have all these preservatives.? It doesn't have to have all these bad colors and stuff like that. . . It's the manufacturer's responsibility. They can make it better. They can make it nutritious, and they can make it accessible. That's what we did in Chobani.?
So what?s next for the company?
Chobani just opened its first retail store, a boutique yogurt bar in SoHo, this summer. Now customers can sit down to enjoy a ?yogurt creation," with gourmet fresh toppings and, of course, Chobani.
Ulukaya is coy about what?s on the horizon for Chobani as far as new products, but he?s clear about one thing: this is only the beginning.
Editor's Note: Harry Smith's full report airs Thursday, Dec. 12 at 10pm/9CT on NBC's Rock Center with Brian Williams.
george strait how i met your mother PNC Bank Jordan Pruitt real housewives of new jersey Kanye West sex tape emmys
Contact: Rick Buck
rick.buck@aacr.org
215-446-7162
American Association for Cancer Research
PHILADELPHIA Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy." Cancer immunology is a field of research that explores the complex relationship between cancer and the immune system, with the goal of discovering immune-based solutions to curing cancer.
The SU2C-CRI Cancer Immunology Translational Research Dream Team will receive $10 million in funding over three years for this translational cancer research project that will unite laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer.
The team will be led by James P. Allison, Ph.D., and Antoni Ribas, M.D., Ph.D. Allison is chairman of the department of immunology, director of the immunotherapy platform and co-director of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center. Ribas is professor of medicine, surgery and molecular and medical pharmacology, director of the tumor immunology program area at the Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA).
"The goal of our Dream Team is to expand, optimize and explore combinations of two novel immunotherapies, immune checkpoint blockade and adoptive T-cell transfer," said Allison. "It is our dream, indeed our expectation, that by optimizing these two uniquely successful and complementary approaches, we will be able achieve durable responses in a large percentage of patients suffering from a variety of types of cancer."
"The SU2C-CRI Dream Team brings together a leading group of tumor immunologists working to speed up the pace of scientific advances to use the immune system to fight cancer," said Ribas.
Co-leaders of the Dream Team are Drew M. Pardoll, M.D., Ph.D., and Cassian Yee, M.D. Pardoll is director of the division of immunology and Abeloff professor in the departments of oncology, medicine, pathology and molecular biology and genetics at the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University in Baltimore, Md. Yee is a member of the Clinical Research Division and program in immunology at Fred Hutchinson Cancer Research Center; a professor of medicine at the University of Washington School of Medicine; and an attending physician at the Seattle Cancer Care Alliance in Seattle, Wash.
Scientists on this Dream Team represent eight institutions: MD Anderson Cancer Center, UCLA, The Johns Hopkins University, Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, California Institute of Technology, Memorial Sloan-Kettering Cancer Center and the Netherlands Cancer Institute.
"The clinical advances in immunotherapy just in the past two years have shown that these strategies indeed empower the patient's own immune system to successfully fight their cancer. Single interventions opened the door; the future is combinatorial therapy, and the synergistic expertise of our Dream Team will catalyze the development of the most innovative combinations," said Pardoll.
"Adoptive T cell therapy in recent years has really come into its own. Novel strategies to generate long-lasting, highly effective T cells are being developed, and in combination with new immunomodulatory agents like the checkpoint inhibitors, we can fully exploit the immune system to treat patients with cancer. We are so fortunate to now have the opportunity to explore these new frontiers in immunotherapy," said Yee.
Significant scientific developments in the field of cancer immunology and the recent FDA approvals of two cancer immunotherapies highlight the field's potential to transform cancer treatment. The formation of this Dream Team focused on this promising area of cancer research aligns with CRI's 60-year mission to advance cancer immunology and SU2C's mission to accelerate the translation of scientific discovery into new treatments for cancer patients.
"Because of my deep respect for the innovative approach to cancer research taken by Stand Up To Cancer, I wanted to support the creation of a team dedicated to this emerging area of research," said tech entrepreneur and philanthropist Sean Parker. "I am delighted that SU2C and the Cancer Research Institute have combined their expertise to select a Dream Team with such great potential to move the field forward through cutting-edge technology and science."
"Cancer immunology, a field which the Cancer Research Institute pioneered and has led for sixty years, is a high-potential area of medical research that is producing some of today's greatest breakthroughs in cancer patient treatment, and I am confident that this Dream Team is going to succeed in making the next great advance," said Jill O'Donnell-Tormey, Ph.D., chief executive officer and director of scientific affairs at CRI.
"Stand Up To Cancer is excited to make this investment in exploring strategies that can activate and enhance the body's own natural ability to fight cancer. The field of cancer immunology is ripe with possible breakthroughs that could change the landscape of cancer treatment, and thus perfectly suited to Stand Up To Cancer's mission to accelerate research that can make more cancer patients survivors," said Sherry Lansing, SU2C co-founder, founder of the Sherry Lansing Foundation, and chairperson of the Entertainment Industry Foundation's (EIF) Board of Directors. (SU2C is a program of EIF, which is a 501(c)3 charitable organization.)
"Along with collaboration, innovation is a pillar of SU2C's model of cancer research, and we are incredibly grateful to have the support of a true innovator in the world of technology like Sean Parker," said SU2C Co-founder Rusty Robertson. "With this immunology-focused Dream Team, we have the opportunity to utilize Sean Parker's generous contribution to advance a cutting-edge field that holds great potential to save lives."
The SU2C-CRI Cancer Immunology Translational Research Project
Cancer immunologists have long hypothesized that specific interventions could stimulate and "re-educate" patients' own immune systems to attack their cancer. In one immunology-based cancer treatment approach, what kills cancer cells is a type of white blood cell called the T lymphocyte. Expanding these T lymphocytes outside the body, engineering them to be more potent and reinfusing these souped up anti-cancer lymphocytes into patients a process termed adoptive cell therapy or ACT is like adding more soldiers to the immune army. However, lymphocytes also have inhibitory receptors, termed checkpoints, that put the brakes on immune responses. Cancers exploit these checkpoints to resist immune attack by the anti-tumor lymphocytes. Blocking checkpoints with specific antibodies disables the brake and allows the immune system to get the upper hand.
The Dream Team will focus on two approaches to overcome these obstacles. First, they will investigate checkpoint blockade, where the checkpoints themselves are inhibited using antibodies, once again allowing T lymphocytes to kill the cancer cells. Second, the team will pursue multiple ACT approaches.
Using tumors obtained from patients, the team will evaluate checkpoint expression before and after ACT and/or checkpoint blockade, and will test the hypothesis that multiple T lymphocyte targets are generated in the tumor. The clinical impact of this project lies with the potential synergy of combining these two immunology-based therapeutic approaches to treat a range of tumor types to improve the lives of patients with cancer.
The project is estimated to start in the spring of 2013, with the first clinical trials scheduled to open in early 2014.
Dream Team Selected Through Unique, Rigorous Process
A SU2C-CRI Joint Scientific Advisory Committee (JSAC) conducted a unique, interactive, rapid and rigorous evaluation of the applications using a multi-step scientific review process. The JSAC is composed of highly accomplished senior laboratory researchers and physician-scientists, as well as patient advocates.
The committee is chaired by Nobel laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. It is co-chaired by Giorgio Trinchieri, M.D., and Carl H. June, M.D. Trinchieri is director of the Cancer and Inflammation Program and chief of the Laboratory of Experimental Immunology at the Center for Cancer Research, National Cancer Institute, and associate director for basic science at the Trans-NIH Center for Human Immunology. June is director of translational research at the Abramson Cancer Center at the University of Pennsylvania, and is an investigator with the Abramson Family Cancer Research Institute. He is also a professor in the department of pathology and laboratory medicine.
The review process began with a call for letters of intent in March of 2012 by the American Association for Cancer Research (AACR), SU2C's scientific partner. The committee then chose four finalist teams, each of which met in person with the JSAC to present plans for their research and respond to questions about their projects a level of interaction between applicants and reviewers that is unique among scientific review processes.
The AACR is responsible for administering the grant and provides ongoing scientific oversight to ensure that progress is being made. Since the launch of Stand Up To Cancer, the AACR has played an integral role as SU2C's scientific partner by providing scientific leadership, expert peer review and grants administration.
Dream Team Principals and Advocate Members
The "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy" Dream Team consists of a multidisciplinary group of experts that includes laboratory and clinical researchers, young investigators and senior scientists who have not worked together in the past, as well as patient advocates. Besides Allison, Ribas, Pardoll and Yee, team members include:
Principals:
Advocates:
Since Stand Up To Cancer's launch in 2008, SU2C has awarded grants to nine Dream Teams and one International Translational Cancer Research Grant. Twenty-six Innovative Research Grants have been awarded to individual young investigators. These recipients comprise more than 450 scientists from 87 institutions.
###
Media Contacts:
SU2C
Adam Pockriss
212-843-8286
apockriss@rubenstein.com
CRI
Brian Brewer
917-676-0871
bbrewer@cancerresearch.org
AACR
Rick Buck
215-446-7162
Rick.Buck@aacr.org
About Stand Up To Cancer
Stand Up To Cancer (SU2C) a program of the Entertainment Industry Foundation (EIF), a 501(c)3 charitable organization raises funds to hasten the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. In the fall of 2007, a group of women whose lives have all been affected by cancer in profound ways began working together to marshal the resources of the media and entertainment industries in the fight against this disease.
Members of the SU2C Executive Leadership Council (ELC) include Talk Show Host, Journalist and well-known Cancer Advocate Katie Couric; Sherry Lansing, Chairperson of the Entertainment Industry Foundation's Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; Pamela Oas Williams, President of Laura Ziskin Productions and Executive Producer of Stand Up To Cancer's In-House Production Team, and Nonprofit Executive Ellen Ziffren. All of the ELC members were co-producers of the 2012 televised special. The late Laura Ziskin, executive producer of both the Sept. 5, 2008 and Sept. 10, 2010 broadcasts, was also a member of the ELC. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C's president and CEO since 2011.
SU2C's "Dream Team" approach to funding translational cancer research enables scientists from different disciplines at research centers across the country and internationally to collaborate on projects geared toward getting new, less toxic treatments to patients as quickly as possible. Monies also support innovative cancer research projects that are often deemed "too risky" by conventional funding sources. Sixty-five institutions are currently involved. As SU2C's scientific collaborator, the American Association for Cancer Research, led by a prestigious SU2C Scientific Advisory Committee, provides scientific oversight, expert review of the research projects and grants administration. For more information, visit standup2cancer.org.
About the Cancer Research Institute
The Cancer Research Institute (CRI), a nonprofit established in 1953, is the global leader in cancer immunology. Since its inception, CRI has invested hundreds of millions of dollars to support research conducted by more than 3,000 scientists and clinicians worldwide to understand the immune system and how it can be harnessed to conquer all cancers. This work has laid the foundation for nearly every major cancer immunotherapy breakthrough over the past half century.
Guided by an international panel of the world's leading immunologists and cancer immunologists, including three Nobel laureates and 29 members of the U.S. National Academy of Sciences, CRI provides essential funding to support every stage of discovery, from laboratory investigation to clinical trials of the most promising cancer immunotherapies for patients.
CRI also sponsors a seminal international symposium on cancer immunology each year, hosts annual scientific colloquia dedicated to overcoming challenges in immunotherapy research and development, forges collaborative partnerships between academia and industry to facilitate the development pathway for novel immunotherapeutics, and presents special recognition awards to individuals who have made outstanding contributions to cancer research, patient care and public awareness.
Through its sustaining support and leadership in the field, CRI is accelerating the development of safe and effective immunotherapies that stand to revolutionize the treatment of all cancers. For more information, visit http://cancerresearch.org or follow CRI on Twitter @CancerResearch.
About the American Association Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional association dedicated to advancing cancer research and preventing and curing cancer. AACR membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org. Follow the AACR on Twitter: @aacr #aacr. Follow the AACR on Facebook: http://www.facebook.com/aacr.org.
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Contact: Rick Buck
rick.buck@aacr.org
215-446-7162
American Association for Cancer Research
PHILADELPHIA Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy." Cancer immunology is a field of research that explores the complex relationship between cancer and the immune system, with the goal of discovering immune-based solutions to curing cancer.
The SU2C-CRI Cancer Immunology Translational Research Dream Team will receive $10 million in funding over three years for this translational cancer research project that will unite laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer.
The team will be led by James P. Allison, Ph.D., and Antoni Ribas, M.D., Ph.D. Allison is chairman of the department of immunology, director of the immunotherapy platform and co-director of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center. Ribas is professor of medicine, surgery and molecular and medical pharmacology, director of the tumor immunology program area at the Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA).
"The goal of our Dream Team is to expand, optimize and explore combinations of two novel immunotherapies, immune checkpoint blockade and adoptive T-cell transfer," said Allison. "It is our dream, indeed our expectation, that by optimizing these two uniquely successful and complementary approaches, we will be able achieve durable responses in a large percentage of patients suffering from a variety of types of cancer."
"The SU2C-CRI Dream Team brings together a leading group of tumor immunologists working to speed up the pace of scientific advances to use the immune system to fight cancer," said Ribas.
Co-leaders of the Dream Team are Drew M. Pardoll, M.D., Ph.D., and Cassian Yee, M.D. Pardoll is director of the division of immunology and Abeloff professor in the departments of oncology, medicine, pathology and molecular biology and genetics at the Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University in Baltimore, Md. Yee is a member of the Clinical Research Division and program in immunology at Fred Hutchinson Cancer Research Center; a professor of medicine at the University of Washington School of Medicine; and an attending physician at the Seattle Cancer Care Alliance in Seattle, Wash.
Scientists on this Dream Team represent eight institutions: MD Anderson Cancer Center, UCLA, The Johns Hopkins University, Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, California Institute of Technology, Memorial Sloan-Kettering Cancer Center and the Netherlands Cancer Institute.
"The clinical advances in immunotherapy just in the past two years have shown that these strategies indeed empower the patient's own immune system to successfully fight their cancer. Single interventions opened the door; the future is combinatorial therapy, and the synergistic expertise of our Dream Team will catalyze the development of the most innovative combinations," said Pardoll.
"Adoptive T cell therapy in recent years has really come into its own. Novel strategies to generate long-lasting, highly effective T cells are being developed, and in combination with new immunomodulatory agents like the checkpoint inhibitors, we can fully exploit the immune system to treat patients with cancer. We are so fortunate to now have the opportunity to explore these new frontiers in immunotherapy," said Yee.
Significant scientific developments in the field of cancer immunology and the recent FDA approvals of two cancer immunotherapies highlight the field's potential to transform cancer treatment. The formation of this Dream Team focused on this promising area of cancer research aligns with CRI's 60-year mission to advance cancer immunology and SU2C's mission to accelerate the translation of scientific discovery into new treatments for cancer patients.
"Because of my deep respect for the innovative approach to cancer research taken by Stand Up To Cancer, I wanted to support the creation of a team dedicated to this emerging area of research," said tech entrepreneur and philanthropist Sean Parker. "I am delighted that SU2C and the Cancer Research Institute have combined their expertise to select a Dream Team with such great potential to move the field forward through cutting-edge technology and science."
"Cancer immunology, a field which the Cancer Research Institute pioneered and has led for sixty years, is a high-potential area of medical research that is producing some of today's greatest breakthroughs in cancer patient treatment, and I am confident that this Dream Team is going to succeed in making the next great advance," said Jill O'Donnell-Tormey, Ph.D., chief executive officer and director of scientific affairs at CRI.
"Stand Up To Cancer is excited to make this investment in exploring strategies that can activate and enhance the body's own natural ability to fight cancer. The field of cancer immunology is ripe with possible breakthroughs that could change the landscape of cancer treatment, and thus perfectly suited to Stand Up To Cancer's mission to accelerate research that can make more cancer patients survivors," said Sherry Lansing, SU2C co-founder, founder of the Sherry Lansing Foundation, and chairperson of the Entertainment Industry Foundation's (EIF) Board of Directors. (SU2C is a program of EIF, which is a 501(c)3 charitable organization.)
"Along with collaboration, innovation is a pillar of SU2C's model of cancer research, and we are incredibly grateful to have the support of a true innovator in the world of technology like Sean Parker," said SU2C Co-founder Rusty Robertson. "With this immunology-focused Dream Team, we have the opportunity to utilize Sean Parker's generous contribution to advance a cutting-edge field that holds great potential to save lives."
The SU2C-CRI Cancer Immunology Translational Research Project
Cancer immunologists have long hypothesized that specific interventions could stimulate and "re-educate" patients' own immune systems to attack their cancer. In one immunology-based cancer treatment approach, what kills cancer cells is a type of white blood cell called the T lymphocyte. Expanding these T lymphocytes outside the body, engineering them to be more potent and reinfusing these souped up anti-cancer lymphocytes into patients a process termed adoptive cell therapy or ACT is like adding more soldiers to the immune army. However, lymphocytes also have inhibitory receptors, termed checkpoints, that put the brakes on immune responses. Cancers exploit these checkpoints to resist immune attack by the anti-tumor lymphocytes. Blocking checkpoints with specific antibodies disables the brake and allows the immune system to get the upper hand.
The Dream Team will focus on two approaches to overcome these obstacles. First, they will investigate checkpoint blockade, where the checkpoints themselves are inhibited using antibodies, once again allowing T lymphocytes to kill the cancer cells. Second, the team will pursue multiple ACT approaches.
Using tumors obtained from patients, the team will evaluate checkpoint expression before and after ACT and/or checkpoint blockade, and will test the hypothesis that multiple T lymphocyte targets are generated in the tumor. The clinical impact of this project lies with the potential synergy of combining these two immunology-based therapeutic approaches to treat a range of tumor types to improve the lives of patients with cancer.
The project is estimated to start in the spring of 2013, with the first clinical trials scheduled to open in early 2014.
Dream Team Selected Through Unique, Rigorous Process
A SU2C-CRI Joint Scientific Advisory Committee (JSAC) conducted a unique, interactive, rapid and rigorous evaluation of the applications using a multi-step scientific review process. The JSAC is composed of highly accomplished senior laboratory researchers and physician-scientists, as well as patient advocates.
The committee is chaired by Nobel laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. It is co-chaired by Giorgio Trinchieri, M.D., and Carl H. June, M.D. Trinchieri is director of the Cancer and Inflammation Program and chief of the Laboratory of Experimental Immunology at the Center for Cancer Research, National Cancer Institute, and associate director for basic science at the Trans-NIH Center for Human Immunology. June is director of translational research at the Abramson Cancer Center at the University of Pennsylvania, and is an investigator with the Abramson Family Cancer Research Institute. He is also a professor in the department of pathology and laboratory medicine.
The review process began with a call for letters of intent in March of 2012 by the American Association for Cancer Research (AACR), SU2C's scientific partner. The committee then chose four finalist teams, each of which met in person with the JSAC to present plans for their research and respond to questions about their projects a level of interaction between applicants and reviewers that is unique among scientific review processes.
The AACR is responsible for administering the grant and provides ongoing scientific oversight to ensure that progress is being made. Since the launch of Stand Up To Cancer, the AACR has played an integral role as SU2C's scientific partner by providing scientific leadership, expert peer review and grants administration.
Dream Team Principals and Advocate Members
The "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy" Dream Team consists of a multidisciplinary group of experts that includes laboratory and clinical researchers, young investigators and senior scientists who have not worked together in the past, as well as patient advocates. Besides Allison, Ribas, Pardoll and Yee, team members include:
Principals:
Advocates:
Since Stand Up To Cancer's launch in 2008, SU2C has awarded grants to nine Dream Teams and one International Translational Cancer Research Grant. Twenty-six Innovative Research Grants have been awarded to individual young investigators. These recipients comprise more than 450 scientists from 87 institutions.
###
Media Contacts:
SU2C
Adam Pockriss
212-843-8286
apockriss@rubenstein.com
CRI
Brian Brewer
917-676-0871
bbrewer@cancerresearch.org
AACR
Rick Buck
215-446-7162
Rick.Buck@aacr.org
About Stand Up To Cancer
Stand Up To Cancer (SU2C) a program of the Entertainment Industry Foundation (EIF), a 501(c)3 charitable organization raises funds to hasten the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. In the fall of 2007, a group of women whose lives have all been affected by cancer in profound ways began working together to marshal the resources of the media and entertainment industries in the fight against this disease.
Members of the SU2C Executive Leadership Council (ELC) include Talk Show Host, Journalist and well-known Cancer Advocate Katie Couric; Sherry Lansing, Chairperson of the Entertainment Industry Foundation's Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; Pamela Oas Williams, President of Laura Ziskin Productions and Executive Producer of Stand Up To Cancer's In-House Production Team, and Nonprofit Executive Ellen Ziffren. All of the ELC members were co-producers of the 2012 televised special. The late Laura Ziskin, executive producer of both the Sept. 5, 2008 and Sept. 10, 2010 broadcasts, was also a member of the ELC. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C's president and CEO since 2011.
SU2C's "Dream Team" approach to funding translational cancer research enables scientists from different disciplines at research centers across the country and internationally to collaborate on projects geared toward getting new, less toxic treatments to patients as quickly as possible. Monies also support innovative cancer research projects that are often deemed "too risky" by conventional funding sources. Sixty-five institutions are currently involved. As SU2C's scientific collaborator, the American Association for Cancer Research, led by a prestigious SU2C Scientific Advisory Committee, provides scientific oversight, expert review of the research projects and grants administration. For more information, visit standup2cancer.org.
About the Cancer Research Institute
The Cancer Research Institute (CRI), a nonprofit established in 1953, is the global leader in cancer immunology. Since its inception, CRI has invested hundreds of millions of dollars to support research conducted by more than 3,000 scientists and clinicians worldwide to understand the immune system and how it can be harnessed to conquer all cancers. This work has laid the foundation for nearly every major cancer immunotherapy breakthrough over the past half century.
Guided by an international panel of the world's leading immunologists and cancer immunologists, including three Nobel laureates and 29 members of the U.S. National Academy of Sciences, CRI provides essential funding to support every stage of discovery, from laboratory investigation to clinical trials of the most promising cancer immunotherapies for patients.
CRI also sponsors a seminal international symposium on cancer immunology each year, hosts annual scientific colloquia dedicated to overcoming challenges in immunotherapy research and development, forges collaborative partnerships between academia and industry to facilitate the development pathway for novel immunotherapeutics, and presents special recognition awards to individuals who have made outstanding contributions to cancer research, patient care and public awareness.
Through its sustaining support and leadership in the field, CRI is accelerating the development of safe and effective immunotherapies that stand to revolutionize the treatment of all cancers. For more information, visit http://cancerresearch.org or follow CRI on Twitter @CancerResearch.
About the American Association Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional association dedicated to advancing cancer research and preventing and curing cancer. AACR membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org. Follow the AACR on Twitter: @aacr #aacr. Follow the AACR on Facebook: http://www.facebook.com/aacr.org.
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-12/aafc-scr121212.php
2012 pro bowl postsecret ufc on fox 2 supercross christina aguilera etta james funeral sundance film festival victoria azarenka